1254 results
Keyword Isoram 4% Remove keyword
-
List item
Press release: New treatment for advanced form of kidney cancer
Last updated: 26/02/2016their tumors compared to 4% of those taking everolimus … their tumors compared to 4% of those taking everolimus … -
List item
News: 10th ESVAC report shows continued decrease in sales of veterinary antibiotics
Last updated: 21/10/2020fluoroquinolones decreased by 4% and sales of other quinolones … -
List item
News: EMA Management Board: highlights of December 2020 meeting
MB, Last updated: 18/12/2020budget increased by about 4% compared to the budget of … -
List item
Orphan designation: Overview
Last updated: 11/05/2023and affect between 3% and 4% of births. Other rare diseases …
-
List item
Human medicine European public assessment report (EPAR): Dovato (updated)
dolutegravir sodium, lamivudine, HIV Infections
Date of authorisation: 10/06/2022, Revision: 14, Authorised, Last updated: 12/09/2023 -
List item
Human medicine European public assessment report (EPAR): Tecfidera (updated)
dimethyl fumarate, Multiple Sclerosis
Date of authorisation: 30/01/2014, Revision: 28, Authorised, Last updated: 20/09/2023 -
List item
Human medicine European public assessment report (EPAR): ellaOne (updated)
ulipristal, Contraception, Postcoital
Date of authorisation: 15/05/2009, Revision: 30, Authorised, Last updated: 19/09/2023 -
List item
Human medicine European public assessment report (EPAR): Rekambys (updated)
rilpivirine, HIV Infections
Date of authorisation: 17/12/2020,
, Revision: 8, Authorised, Last updated: 05/09/2023
-
List item
Human medicine European public assessment report (EPAR): Entyvio (updated)
vedolizumab, Colitis, Ulcerative; Crohn Disease
Date of authorisation: 22/05/2014, Revision: 25, Authorised, Last updated: 14/09/2023 -
List item
Human medicine European public assessment report (EPAR): Erleada (updated)
apalutamide, Prostatic Neoplasms
Date of authorisation: 14/01/2019,, Revision: 10, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Herzuma (updated)
trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 09/02/2018,
, Revision: 20, Authorised, Last updated: 20/09/2023
-
List item
Human medicine European public assessment report (EPAR): Docetaxel Accord (updated)
docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Breast Neoplasms
Date of authorisation: 22/05/2012,
, Revision: 17, Authorised, Last updated: 14/09/2023
-
List item
Human medicine European public assessment report (EPAR): Revinty Ellipta (updated)
fluticasone furoate, vilanterol trifenatate, Asthma
Date of authorisation: 02/05/2014, Revision: 22, Authorised, Last updated: 04/09/2023 -
List item
Human medicine European public assessment report (EPAR): Rixathon (updated)
rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Wegener Granulomatosis; Microscopic Polyangiitis; Pemphigus
Date of authorisation: 15/06/2017,, Revision: 11, Authorised, Last updated: 18/09/2023
-
List item
Human medicine European public assessment report (EPAR): Riximyo (updated)
rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis; Wegener Granulomatosis
Date of authorisation: 15/06/2017,, Revision: 13, Authorised, Last updated: 18/09/2023
-
List item
Human medicine European public assessment report (EPAR): Relvar Ellipta (updated)
fluticasone furoate, vilanterol, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 13/11/2013, Revision: 25, Authorised, Last updated: 04/09/2023 -
List item
Human medicine European public assessment report (EPAR): Imbruvica (updated)
Ibrutinib, Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 21/10/2014, Revision: 31, Authorised, Last updated: 22/09/2023 -
List item
Human medicine European public assessment report (EPAR): Lutathera (updated)
lutetium (177Lu) oxodotreotide, Neuroendocrine Tumors
Date of authorisation: 26/09/2017,
, Revision: 10, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Apretude (updated)
Cabotegravir, HIV Infections
Date of authorisation: 15/09/2023, Authorised, Last updated: 20/09/2023 -
List item
Human medicine European public assessment report (EPAR): Ninlaro (updated)
ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016,, , 
, Revision: 16, Authorised, Last updated: 05/09/2023
-
List item
Human medicine European public assessment report (EPAR): Tafinlar (updated)
dabrafenib mesilate, Melanoma
Date of authorisation: 26/08/2013, Revision: 29, Authorised, Last updated: 01/09/2023 -
List item
Human medicine European public assessment report (EPAR): Tremelimumab AstraZeneca (updated)
Tremelimumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/02/2023,, Revision: 1, Authorised, Last updated: 11/09/2023
-
List item
Human medicine European public assessment report (EPAR): Epclusa
Sofosbuvir, velpatasvir, Hepatitis C, Chronic
Date of authorisation: 06/07/2016,
, Revision: 21, Authorised, Last updated: 14/08/2023
-
List item
Human medicine European public assessment report (EPAR): Vitrakvi (updated)
larotrectinib sulfate, Abdominal Neoplasms
Date of authorisation: 19/09/2019,, , Revision: 10, Authorised, Last updated: 22/09/2023
-
List item
Human medicine European public assessment report (EPAR): Litfulo (updated)
ritlecitinib tosilate, Alopecia Areata
Date of authorisation: 15/09/2023,, Authorised, Last updated: 18/09/2023